>Feedback from the road show with management - At a road show with Elis’ management (CEO, CFO, HIR, IR), we reviewed the group's news and mainly the possibility of acquiring Vestis. Our key takeaways: from a strategic viewpoint, Elis reiterated that the North American market represents $ 48bn (including $ 21bn for "uniforms"), i.e. 2x the size of the addressable market in Europe with average annual growth of 5-6% (vs around 3-4% in Europe). On the competition fro...
>Feedback roadshow management - A l’occasion d’un roadshow avec le management (CEO, CFO, HIR, IR), nous sommes revenus sur l’actualité du groupe et principalement sur la possibilité d’une acquisition de Vestis. Nous retiendrons principalement que : D’un point de vue stratégique, le groupe Elis rappelle que le marché en Amérique du nord représente 48 Md$ (dont 21 Md$ pour les « Uniforms ») soit 2x la taille du marché adressable en Europe avec une croissance annuel...
OSE Immunotherapeutics has announced the initiation of its Phase III registrational study (Artemia) for lead cancer vaccine Tedopi, with the trial launching in the US, Canada, Europe and the UK. Artemia is a confirmatory pivotal trial designed to assess the efficacy and safety of Tedopi as a monotherapy versus the standard of care (SoC) in HLA-A2 positive patients with metastatic non-small cell lung cancer (NSCLC) and secondary (acquired) resistance to immune checkpoint inhibitors (ICIs). The pr...
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer Trial begins in the United States, Canada, Europe and United Kingdom after successful regulatory authorizations in 14 countries.Trial in Progress presentation at the 2024 World Conference on Lung Cancer in San Diego and at the European Society for Medical Oncology congress 2024 in Bar...
At the 15th edition of our Corporate Conference, hosted jointly by ODDO BHF and Commerzbank, the presenting corporates were still focused on the macroeconomic environment and the related impact on their sectors. Regionally, the US remains resilient at good levels, while China and Europe are lagging behind. Germany in particular is seen as sluggish. Hence, we observed a mixed picture across the 89 companies presenting at our conference. We were positively surprised by statements from a...
At the 15th edition of our Corporate Conference, hosted jointly by ODDO BHF and Commerzbank, the presenting corporates were still focused on the macroeconomic environment and the related impact on their sectors. Regionally, the US remains resilient at good levels, while China and Europe are lagging behind. Germany in particular is seen as sluggish. Hence, we observed a mixed picture across the 89 companies presenting at our conference. We were positively surprised by statements from a...
>Elis confirmed on Friday that it had approached Vestis with a view to an acquisition - On Friday, Elis’ share price dropped by 15.66% after a Reuters article indicated that the group had approached Vestis (VSTS) regarding a potential acquisition. This rumour was confirmed by Elis’ management in a press release during the day, which said that the approach was only preliminary and that there was no guarantee discussions would lead to the signature of a transaction or a...
>Elis a confirmé vendredi avoir approché Vestis en vue d’une acquisition - Vendredi, le cours d’Elis a reculé de 15.66% après un article de Reuters indiquant que le groupe avait approché Vestis (VSTS) concernant une potentielle acquisition. Cette rumeur a été confirmée par le management d’Elis dans un communiqué en cours de journée, disant que cette approche n’était que préliminaire et qu’il n’y avait aucune garantie que les discussions aboutissent à la signature d’un...
Elis to host a webcast as part of non-deal roadshow Saint-Cloud, 8 September 2024 – Elis’ management opens tomorrow, Monday 9 September, a previously scheduled non-deal investor roadshow during which the company will discuss its business and strategy. As part of this two-week roadshow, Elis will host a webcast presentation and question-and-answer session for investors and analysts on Monday September 9 at 8:00am CET with Xavier Martiré, Chairman of the Management Board and Louis Guyot, Chief Financial Officer. The link to the webcast is: The link to the conference call & Q&A session is:...
Elis: Press release Saint-Cloud, 6 September 2024 – Elis confirms it has made a preliminary approach to Vestis regarding a potential acquisition. Elis regularly considers a range of strategic opportunities. There can be no assurance that these discussions will result in the signing of a transaction or other agreement. Any transaction, should one be agreed, would be in line with Elis’ commitments to its shareholders, namely: Financial discipline in terms of the amount paid for the acquisition;Retain investment grade rating and leverage of c. 2.2x adjusted EBITDA in Year 1 and c. 2.0x in...
Elis: Disclosure of the number of shares forming the capital and of the total number of voting rights as of 31 08 2024 DECLARATION DU NOMBRE D’ACTIONS COMPOSANT LE CAPITALET DU NOMBRE TOTAL DE DROITS DE VOTE AU 31 AOUT 2024 Article L. 233-8-II du Code de CommerceArticle 223-16 du Règlement général de l’AMF Nombre d’actions composant le capital social235 567 817Nombre de droits de vote théoriques267 565 661Nombre de droits de vote exerçables267 512 953 Cette déclaration est en ligne sur le site internet d’Elis DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITALAND OF THE TOTAL NUMBER O...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.